Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial

BACKGROUND: A paucity of strategies exist for extensive-stage small cell lung cancer (ES-SCLC) patients who fail the first-line chemotherapy. Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), which has been demonstrated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Quan, Xu, Juan-Ying, Xu, Ye-Hong, Chen, Meng, Deng, Li-Chun, Wu, Jian-Ping, Zhou, Tong, Zhang, Li-Qin, Tan, Jie, Pu, Xing-Xiang, Shang, Yu-Long, Hua, Jun, Li, Yuan-Qin, Cai, Wei, Gu, Yu-Lan, Peng, Xing-Chen, Chan, Po-Chung, Jabbour, Salma K., Nam, Hae-Seong, Hua, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186180/
https://www.ncbi.nlm.nih.gov/pubmed/35693282
http://dx.doi.org/10.21037/tlcr-22-313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186180/
https://www.ncbi.nlm.nih.gov/pubmed/35693282
http://dx.doi.org/10.21037/tlcr-22-313

Ejemplares similares